Gloucester Pharma Snags $29 Million Series D
This article was originally published in The Pink Sheet Daily
Executive Summary
As Gloucester Pharma preps for the FDA, the blood-borne cancer developer corrals a D round from Novo and others to gain leverage in partnering talks.